Clinical Trials Directory

Trials / Completed

CompletedNCT05245708

Effects of Oxytocin on Reinforcement Learning and Interoception

The Modulatory Effects of Oxytocin on Reinforcement Learning and Interoceptive Processing

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
80 (actual)
Sponsor
University of Electronic Science and Technology of China · Academic / Other
Sex
Male
Age
18 Years – 28 Years
Healthy volunteers
Accepted

Summary

The main aim of the study is to investigate whether intranasal oxytocin has effects on reinforcement learning under dynamic environment and interoceptive processing based on behavioral and electroencephalogram (EEG) responses.

Detailed description

A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. (1) Participants first complete a probabilistic reward learning task 45 minutes after treatment with behavioral (response time and accuracy) and EEG data (ERP components such as FRN, ERN and P300) being collected during this task. (2) A resting-state recording and a heartbeat counting task are conducted following the learning task with ECG and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), the Cognitive Flexibility Inventory(CFI), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the tasks.

Conditions

Interventions

TypeNameDescription
DRUGIntranasal oxytocinEach subject will be assigned to intranasal administration of oxytocin (24 IU).
DRUGintranasal placeboEach subject will be assigned to intranasal placebo.

Timeline

Start date
2021-04-15
Primary completion
2021-09-20
Completion
2021-12-15
First posted
2022-02-18
Last updated
2024-01-19

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05245708. Inclusion in this directory is not an endorsement.